MCID: BNR002
MIFTS: 54

Bone Resorption Disease

Categories: Bone diseases

Aliases & Classifications for Bone Resorption Disease

MalaCards integrated aliases for Bone Resorption Disease:

Name: Bone Resorption Disease 12 15
Bone Resorption 45

Classifications:



External Ids:

Disease Ontology 12 DOID:0080011
MeSH 45 D001862

Summaries for Bone Resorption Disease

Disease Ontology : 12 A bone remodeling disease that results in an abnormal decrease of bone density or mass.

MalaCards based summary : Bone Resorption Disease, also known as bone resorption, is related to osteopetrosis and osteitis fibrosa. An important gene associated with Bone Resorption Disease is BGLAP (Bone Gamma-Carboxyglutamate Protein), and among its related pathways/superpathways are RANK Signaling in Osteoclasts and Osteoclast differentiation. The drugs Nitric Oxide and Isosorbide Dinitrate have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotypes are cellular and growth/size/body region

Wikipedia : 77 Bone resorption is resorption of bone tissue, that is, the process by which osteoclasts break down the... more...

Related Diseases for Bone Resorption Disease

Diseases related to Bone Resorption Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 osteopetrosis 32.5 CTSK LRP5 TNFRSF11A TNFSF11
2 osteitis fibrosa 32.3 BGLAP CALCA PTH
3 paget disease of bone 5, juvenile-onset 32.1 CALCA TNFRSF11A TNFRSF11B TNFSF11
4 glucocorticoid-induced osteoporosis 31.8 ACP5 BGLAP BMP2 CALCA IGF1 PTH
5 periodontitis 31.3 BGLAP CTSK RUNX2 TNFRSF11B TNFSF11
6 periodontal disease 31.1 TNFRSF11A TNFRSF11B TNFSF11
7 rheumatoid arthritis 30.9 ACP5 CTSK TNFRSF11A TNFRSF11B TNFSF11
8 periapical periodontitis 30.8 ACP5 TNFRSF11A TNFRSF11B TNFSF11
9 idiopathic hypercalciuria 30.7 BGLAP TNFSF11 VDR
10 osteoporotic fracture 30.7 ESR1 TNFRSF11B
11 hyperparathyroidism 30.6 ACP5 BGLAP CALCA PTH TNFRSF11B VDR
12 giant cell tumor 30.6 BGLAP CALCA CTSK TNFRSF11A TNFRSF11B TNFSF11
13 paget's disease of bone 30.5 BGLAP CALCA TNFRSF11A TNFRSF11B TNFSF11
14 bone giant cell tumor 30.5 ACP5 CALCA CTSK TNFSF11
15 primary hyperparathyroidism 30.5 BGLAP CALCA PTH VDR
16 bone inflammation disease 30.4 ACP5 BGLAP CTSK TNFRSF11B TNFSF11
17 uremia 30.4 PTH TNFRSF11B VDR
18 rickets 30.4 BGLAP PTH VDR
19 multicentric reticulohistiocytosis 30.3 TNFRSF11B TNFSF11
20 osteonecrosis 30.3 ACP5 BGLAP BMP2 PTH RUNX2 TNFRSF11B
21 hemophilic arthropathy 30.3 TNFRSF11A TNFRSF11B TNFSF11
22 renal osteodystrophy 30.2 BGLAP CALCA PTH SOST TNFRSF11B VDR
23 osteogenesis imperfecta, type i 30.2 BGLAP IGF1 TNFRSF11B
24 osteomalacia 30.1 BGLAP CALCA PTH VDR
25 hypervitaminosis d 30.1 PTH VDR
26 bone cancer 30.1 ESR1 TNFRSF11A TNFSF11
27 root resorption 30.0 CALCA CTSK RUNX2 TNFRSF11A TNFRSF11B TNFSF11
28 osteoporosis 30.0 ACP5 BGLAP BMP2 CALCA CTSK ESR1
29 breast adenocarcinoma 30.0 CALCA CTSK ESR1 TNFSF11
30 chronic kidney failure 30.0 BGLAP CALCA IGF1 PTH TNFRSF11B VDR
31 insulin-like growth factor i 29.9 BGLAP ESR1 IGF1
32 calciphylaxis 29.7 PTH VDR
33 bone disease 29.4 ACP5 BGLAP CALCA CTSK IGF1 LRP5
34 bone remodeling disease 29.1 ACP5 BGLAP BMP2 CALCA CTSK ESR1
35 hajdu-cheney syndrome 11.0
36 failure of tooth eruption, primary 11.0
37 paget disease of bone 3 11.0
38 singleton-merten syndrome 1 11.0
39 osteopetrosis, autosomal recessive 5 11.0
40 paget disease of bone 2, early-onset 11.0
41 osteopetrosis, autosomal dominant 1 11.0
42 osteopetrosis, autosomal recessive 8 11.0
43 hyperparathyroidism 4 11.0
44 ameloblastic carcinoma 11.0
45 arthritis 10.6
46 axial osteomalacia 10.5 BGLAP PTH
47 extraskeletal chondroma 10.5 BGLAP PTH
48 breast cancer 10.5
49 pseudoarthrosis 10.5 BMP2 PTH
50 fibrogenesis imperfecta ossium 10.5 CALCA PTH TNFRSF11B

Graphical network of the top 20 diseases related to Bone Resorption Disease:



Diseases related to Bone Resorption Disease

Symptoms & Phenotypes for Bone Resorption Disease

MGI Mouse Phenotypes related to Bone Resorption Disease:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
2 growth/size/body region MP:0005378 10.33 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
3 homeostasis/metabolism MP:0005376 10.25 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
4 cardiovascular system MP:0005385 10.24 BMP2 ESR1 IGF1 LRP5 NFATC1 PTH
5 craniofacial MP:0005382 10.21 BMP2 CTSK LRP5 NFATC1 PTH RUNX2
6 hematopoietic system MP:0005397 10.21 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
7 immune system MP:0005387 10.18 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
8 endocrine/exocrine gland MP:0005379 10.13 CTSK ESR1 IGF1 LRP5 PTH RUNX2
9 limbs/digits/tail MP:0005371 10.13 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1
10 digestive/alimentary MP:0005381 10.1 BMP2 CTSK ESR1 NFATC1 RUNX2 SLC51A
11 mortality/aging MP:0010768 9.97 BMP2 ESR1 IGF1 LRP5 NFATC1 PTH
12 integument MP:0010771 9.92 ESR1 IGF1 NFATC1 RPL24 RUNX2 TNFRSF11A
13 respiratory system MP:0005388 9.56 CTSK ESR1 IGF1 NFATC1 RUNX2 SP7
14 skeleton MP:0005390 9.5 BMP2 CTSK ESR1 IGF1 LRP5 NFATC1

Drugs & Therapeutics for Bone Resorption Disease

Drugs for Bone Resorption Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 413)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 3 10102-43-9 145068
2
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3 87-33-2 6883
3
AT-101 Approved, Investigational Phase 4,Phase 3 90141-22-3, 652-67-5 12597
4 sodium fluoride Approved Phase 4 7681-49-4
5
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 615258-40-7
6
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 52232-67-4 16133850
7
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9002-64-6
8
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
9
Anastrozole Approved, Investigational Phase 4,Phase 2 120511-73-1 2187
10
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2,Early Phase 1 5949-44-0
11
Testosterone enanthate Approved Phase 4,Phase 2,Early Phase 1 315-37-7 9416
12
Methyltestosterone Approved Phase 4,Phase 2,Early Phase 1 58-18-4 6010
13
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2,Early Phase 1 58-22-0, 481-30-1 10204 6013
14
Alendronate Approved Phase 4,Phase 2,Phase 3,Not Applicable 66376-36-1, 121268-17-5 2088
15
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
16
Risedronate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 105462-24-6 5245
17
Phylloquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 84-80-0
18 Menaquinone Approved, Investigational Phase 4,Phase 3,Not Applicable 1182-68-9
19
Atorvastatin Approved Phase 4 134523-00-5 60823
20
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 50-28-2 5757
21
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
22
Polyestradiol phosphate Approved Phase 4,Phase 3,Not Applicable 28014-46-2
23
Potassium Citrate Approved, Investigational, Vet_approved Phase 4,Not Applicable
24
Sodium Citrate Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68-04-2
25
Etidronic acid Approved Phase 4,Phase 3,Phase 1,Phase 2 7414-83-7, 2809-21-4 3305
26
Liraglutide Approved Phase 4 204656-20-2 44147092
27
Norelgestromin Approved, Investigational Phase 4 53016-31-2 13752005
28
Mecasermin Approved, Investigational Phase 4 68562-41-4
29
Desogestrel Approved Phase 4 54024-22-5 40973
30
Ethinyl Estradiol Approved Phase 4,Phase 3 57-63-6 5991
31
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
32
tannic acid Approved Phase 4,Not Applicable 1401-55-4
33
Benzocaine Approved, Investigational Phase 4,Not Applicable 1994-09-7, 94-09-7 2337
34
Demeclocycline Approved Phase 4 127-33-3 5311063
35
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
36
Adalimumab Approved Phase 4,Phase 3,Not Applicable 331731-18-1 16219006
37
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 1,Phase 2 9004-61-9 53477741
38
Salmon Calcitonin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 47931-85-1 16129616
39
Metronidazole Approved Phase 4 443-48-1 4173
40
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
41
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7440-70-2 271
42
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-16-2
43
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-14-6 5280793
44
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 67-97-0 5280795 6221
45
Menadione Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 58-27-5 4055
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 77-92-9 311
47
Calcitriol Approved, Nutraceutical Phase 4,Phase 2 32222-06-3 5280453 134070
48
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 1 73-31-4 896
49
Vitamin C Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 50-81-7 54670067 5785
50
Menatetrenone Investigational Phase 4 863-61-6 5282367

Interventional clinical trials:

(show top 50) (show all 533)
# Name Status NCT ID Phase Drugs
1 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
2 Clinical and Microbiological Effects of an Essential Oils Solution Used as an Adjunct to Daily Oral Hygiene Practices in Chronic Periodontitis Patients in Supportive Care Unknown status NCT01195493 Phase 4
3 Bone Turnover in Type 2 Diabetes Patients Unknown status NCT00732121 Phase 4 Sitagliptin;Placebo
4 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
5 The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty Completed NCT02760979 Phase 4 Denosumab;Placebo
6 A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate) Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
7 Sodium Alendronate in Non Surgical Periodontal Therapy Completed NCT02470611 Phase 4 Sodium alendronate
8 Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) Completed NCT00479037 Phase 4 Full Length Parathyroid Hormone, PTH(1-84);Strontium Ranelate
9 Does Omeprazole Decrease Intestinal Calcium Absorption? Completed NCT00582972 Phase 4 Omeprazole
10 Bone Mineral Changes Around Stemless and Stemmed Cementless Femoral Components Completed NCT00957970 Phase 4
11 A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of SPI Implant Completed NCT02367261 Phase 4
12 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women With Bone Loss Completed NCT00460057 Phase 4 Alendronate
13 Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window? Completed NCT01166958 Phase 4 Teriparatide;Raloxifene
14 POWER Point of Care Effect on Satisfaction of Treatment Completed NCT00549068 Phase 4 Risedronate Sodium (Actonel)
15 Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta Completed NCT02303873 Phase 4 Alendronate
16 A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis Completed NCT02598934 Phase 4 Ibandronate
17 Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis Completed NCT01535027 Phase 4 teriparatide;teriparatide and raloxifene;teriparatide and alendronate
18 The Effect of Vitamin K2 on Bone Turnover Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
19 Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy Completed NCT00485953 Phase 4 risedronate
20 Atorvastatin as an Adjunct to DFDBA in Intrabony Defects Completed NCT03009097 Phase 4 DFDBA with atorvastatin
21 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
22 The Effects of Potassium Citrate on Bone Metabolism Completed NCT00357331 Phase 4 potassium citrate
23 Risedronate Sodium in Post Menopausal Osteoporosis Completed NCT00453492 Phase 4 risedronate sodium
24 Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption? Completed NCT00766532 Phase 4 Aromatase Inhibitor
25 Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis Completed NCT02808988 Phase 4
26 The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function Completed NCT02473809 Phase 4 Liraglutide;Placebo
27 Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD Completed NCT01745848 Phase 4 Roflumilast
28 A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis. Completed NCT00377234 Phase 4 Risedronate;ibandronate [Bonviva/Boniva]
29 Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis Completed NCT02367833 Phase 4 Combined Oral Contraceptive;Transdermal Contraceptive;Contraceptive Vaginal Ring
30 Efficacy of Zoledronic Acid in Enhancement of Early Stability of Cementless Primary Hip Prosthesis Completed NCT01218035 Phase 4 zoledronic acid
31 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) Completed NCT01350934 Phase 4 alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus);Calcitriol
32 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
33 A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva Completed NCT00081653 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
34 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed NCT00545363 Phase 4 Ibandronate
35 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed NCT00545051 Phase 4 Placebo;ibandronate
36 Bone Loss in Premenopausal Women With Depression Completed NCT00006180 Phase 4 Alendronate
37 Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid
38 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4 Anastrozole;Risedronate Sodium
39 Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed NCT01753856 Phase 4 Teriparatide;Denosumab;Demeclocycline;Tetracycline;Calcium Supplement;Vitamin D
40 A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia Completed NCT00129623 Phase 4 Placebo;ibandronate [Bonviva/Boniva]
41 A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide Completed NCT00557310 Phase 4 teriparatide
42 Do We Need High-Flexing Total Knee Arthroplasty to Improve the Survivorship and to Decrease the Incidence of Osteolysis? Completed NCT01422642 Phase 4
43 The Influence of Dimensional Anatomic Variables on the Outcomes of Maxillary Sinus Grafting Procedures Completed NCT00868777 Phase 4
44 Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft Completed NCT02218515 Phase 4
45 Bone Resorption, Osteoclastogenesis and Adalimumab Recruiting NCT02035800 Phase 4 Adalimumab
46 Alveolar Management Following Teeth Extraction Recruiting NCT03089619 Phase 4 Human-Spongiosa
47 Prolonged Protection From Bone Disease in Multiple Myeloma Recruiting NCT02286830 Phase 4 Zoledronic acid
48 Denosumab Sequential Therapy Recruiting NCT03868033 Phase 4 Zoledronic Acid;Denosumab
49 Use of the xCELLigence System for Quantification of Bacterial Biofilm's Real Time Formation and Antibiotics Selection. Recruiting NCT03863249 Phase 4 ADJUNTIVE ANTIBIOTICS
50 Assessing the Impact of Contraceptives on Bone Health Using 41Ca Active, not recruiting NCT02367846 Phase 4 Combined Oral Contraceptive (COC);Contraceptive Vaginal Ring (CVR)

Search NIH Clinical Center for Bone Resorption Disease

Cochrane evidence based reviews: bone resorption

Genetic Tests for Bone Resorption Disease

Anatomical Context for Bone Resorption Disease

MalaCards organs/tissues related to Bone Resorption Disease:

42
Bone, Breast, Prostate, Bone Marrow, Kidney, T Cells, Monocytes

Publications for Bone Resorption Disease

Articles related to Bone Resorption Disease:

(show top 50) (show all 3040)
# Title Authors Year
1
MiR-146a-5p Expression in Peripheral CD14⁺ Monocytes from Patients with Psoriatic Arthritis Induces Osteoclast Activation, Bone Resorption, and Correlates with Clinical Response. ( 30658492 )
2019
2
Liraglutide increases bone formation and inhibits bone resorption in rats with glucocorticoid-induced osteoporosis. ( 30955181 )
2019
3
Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice. ( 30700417 )
2019
4
Increased bone resorption in hemophilia. ( 29857920 )
2019
5
Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα. ( 30604211 )
2019
6
Bone resorption in dogs with calcium oxalate urolithiasis and idiopathic hypercalciuria. ( 30641472 )
2019
7
Medication-related osteonecrosis of the jaw incidence in patients exposed concomitantly to bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors: is it generalizable to all solid tumors? ( 29860712 )
2019
8
Interferon gamma-1b does not increase markers of bone resorption in autosomal dominant osteopetrosis. ( 30889272 )
2019
9
Cumambrin A prevents OVX-induced osteoporosis via the inhibition of osteoclastogenesis, bone resorption, and RANKL signaling pathways. ( 30807230 )
2019
10
IL-22-expressing CD4+ AhR+ T lymphocytes are associated with RANKL-mediated alveolar bone resorption during experimental periodontitis. ( 31032952 )
2019
11
Elevated Expression of Macrophage Migration Inhibitory Factor Promotes Inflammatory Bone Resorption Induced in a Mouse Model of Periradicular Periodontitis. ( 30737274 )
2019
12
Notch signaling pathway mediates alveolar bone resorption in apical periodontitis. ( 30798925 )
2019
13
Aminothiazoles inhibit osteoclastogenesis and PGE2 production in LPS-stimulated co-cultures of periodontal ligament and RAW 264.7 cells, and RANKL-mediated osteoclastogenesis and bone resorption in PBMCs. ( 30506812 )
2019
14
Macrophage polarization in aseptic bone resorption around dental implants induced by Ti particles in a murine model. ( 30635919 )
2019
15
Efficacy of injectable platelet-rich plasma in reducing alveolar bone resorption following rapid maxillary expansion: A cone-beam computed tomography assessment in a randomized split-mouth controlled trial. ( 30920874 )
2019
16
Bone Resorption Triggered by High Radial Stress: The Mechanism of Screw Loosening in Plate Fixation of Long Bone Fractures. ( 30908687 )
2019
17
Docosahexaenoic Acid Inhibits Inflammation-Induced Osteoclast Formation and Bone Resorption in vivo Through GPR120 by Inhibiting TNF-α Production in Macrophages and Directly Inhibiting Osteoclast Formation. ( 30949128 )
2019
18
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption. ( 30956999 )
2019
19
Fluorine-contained hydroxyapatite suppresses bone resorption through inhibiting osteoclasts differentiation and function in vitro and in vivo. ( 30968984 )
2019
20
Catabolic activity of osteoblast-lineage cells contributes to osteoclastic bone resorption in vitro. ( 30975918 )
2019
21
Cortical bone resorption of fibular bone after maxillary reconstruction with a vascularized fibula free flap: a computed tomography imaging study. ( 30979515 )
2019
22
Unexpected Role of Matrix Gla Protein in Osteoclasts: Inhibiting Osteoclast Differentiation and Bone Resorption. ( 30988158 )
2019
23
Effects of 12-week combined exercise on RANKL/RANK/OPG signaling and bone-resorption cytokines in healthy college females. ( 31010270 )
2019
24
An Ectosteric Inhibitor of Cathepsin K Inhibits Bone Resorption in Ovariectomized Mice. ( 31018028 )
2019
25
The AmyI-1-18 peptide derived from rice inhibits alveolar bone resorption via suppression of inflammatory cytokine production induced by lipopolysaccharide and interleukin-1β in mice. ( 31032912 )
2019
26
Masticatory function in complete denture wearers varying degree of mandibular bone resorption and occlusion concept: canine-guided occlusion versus bilateral balanced occlusion in a cross-over trial. ( 31047845 )
2019
27
Bee venom attenuates Porphyromonas gingivalis and RANKL-induced bone resorption with osteoclastogenic differentiation. ( 31055000 )
2019
28
Interleukin‑17A facilitates osteoclast differentiation and bone resorption via activation of autophagy in mouse bone marrow macrophages. ( 31059030 )
2019
29
Vav1 inhibits RANKL-induced osteoclast differentiation and bone resorption. ( 31072447 )
2019
30
Osthole inhibits osteoclasts formation and bone resorption by regulating NF-κB signaling and NFATc1 activations stimulated by RANKL. ( 31081953 )
2019
31
SLIT2 inhibits osteoclastogenesis and bone resorption by suppression of Cdc42 activity. ( 31084928 )
2019
32
Bone resorption and body reorganization during maturation induce maternal transfer of toxic metals in anguillid eels. ( 31085642 )
2019
33
Short-chain fatty acids and FFAR2 as suppressors of bone resorption. ( 31100533 )
2019
34
C1 Silencing Attenuates Inflammation and Alveolar Bone Resorption in Endodontic Disease. ( 31104818 )
2019
35
Premaxilla Stress Distribution and Bone Resorption Induced by Implant Overdenture and Conventional Denture. ( 30044033 )
2019
36
LncRNA AK077216 promotes RANKL-induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45. ( 30132869 )
2019
37
Conditioned fear stress increases bone resorption in apical periodontitislesions in Wistar male rats. ( 30339914 )
2019
38
A novel Bruton's tyrosine kinase inhibitor, acalabrutinib, suppresses osteoclast differentiation and Porphyromonas gingivalis lipopolysaccharide-induced alveolar bone resorption. ( 30387495 )
2019
39
DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo. ( 30396082 )
2019
40
Underhang of the tibial component increases tibial bone resorption after total knee arthroplasty. ( 30470851 )
2019
41
MicroRNA‑100‑5p inhibits osteoclastogenesis and bone resorption by regulating fibroblast growth factor 21. ( 30535435 )
2019
42
Sphingosine-1-Phosphate Receptor 2 Controls Podosome Components Induced by RANKL Affecting Osteoclastogenesis and Bone Resorption. ( 30609675 )
2019
43
Bone resorption in autologous cryopreserved cranioplasty: quantitative evaluation, semiquantitative score and clinical significance. ( 30617716 )
2019
44
Osteoclasts secrete osteopontin into resorption lacunae during bone resorption. ( 30637455 )
2019
45
Tenofovir Causes Bone Loss via Decreased Bone Formation and Increased Bone Resorption, Which Can Be Counteracted by Dipyridamole in Mice. ( 30645771 )
2019
46
Modification of honeycomb bioceramic scaffolds for bone regeneration under the condition of excessive bone resorption. ( 30707498 )
2019
47
Beta-Cryptoxanthin Inhibits Lipopolysaccharide-Induced Osteoclast Differentiation and Bone Resorption via the Suppression of Inhibitor of NF-κB Kinase Activity. ( 30744180 )
2019
48
Periradicular inflammatory response, bone resorption, and cementum repair after sealing of furcation perforation with mineral trioxide aggregate (MTA Angelus™) or Biodentine™. ( 30864115 )
2019
49
A dried blood spot-based method to measure levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), a marker of bone resorption. ( 30897260 )
2019
50
Relationship between melatonin and bone resorption rhythms in premenopausal women. ( 29318392 )
2019

Variations for Bone Resorption Disease

Expression for Bone Resorption Disease

Search GEO for disease gene expression data for Bone Resorption Disease.

Pathways for Bone Resorption Disease

GO Terms for Bone Resorption Disease

Cellular components related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 BGLAP BMP2 CALCA CTSK IGF1 PTH
2 extracellular space GO:0005615 9.28 BGLAP BMP2 CALCA CTSK IGF1 PTH

Biological processes related to Bone Resorption Disease according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.98 BMP2 IGF1 RUNX2 TNFSF11 VDR
2 positive regulation of transcription by RNA polymerase II GO:0045944 9.96 BMP2 ESR1 IGF1 LRP5 NFATC1 PTH
3 regulation of signaling receptor activity GO:0010469 9.93 BMP2 CALCA IGF1 PTH TNFRSF11B TNFSF11
4 cell-cell signaling GO:0007267 9.91 BMP2 CALCA PTH TNFRSF11A
5 positive regulation of transcription, DNA-templated GO:0045893 9.91 BMP2 ESR1 IGF1 LRP5 NFATC1 RUNX2
6 animal organ morphogenesis GO:0009887 9.83 BMP2 TNFSF11 VDR
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.82 ESR1 TNFRSF11A TNFSF11
8 osteoblast differentiation GO:0001649 9.81 BGLAP BMP2 RUNX2 SP7
9 tumor necrosis factor-mediated signaling pathway GO:0033209 9.78 TNFRSF11A TNFRSF11B TNFSF11
10 response to estrogen GO:0043627 9.77 BGLAP ESR1 TNFRSF11B
11 monocyte chemotaxis GO:0002548 9.73 CALCA TNFRSF11A TNFSF11
12 positive regulation of bone resorption GO:0045780 9.65 TNFRSF11A TNFSF11
13 positive regulation of glycogen biosynthetic process GO:0045725 9.64 IGF1 PTH
14 cellular calcium ion homeostasis GO:0006874 9.64 PTH VDR
15 regulation of osteoclast differentiation GO:0045670 9.63 BGLAP TNFSF11
16 positive regulation of ossification GO:0045778 9.63 BMP2 PTH
17 negative regulation of bone resorption GO:0045779 9.62 CALCA TNFRSF11B
18 response to inorganic substance GO:0010035 9.62 BGLAP TNFRSF11B
19 positive regulation of osteoblast differentiation GO:0045669 9.62 BMP2 IGF1 LRP5 RUNX2
20 osteoblast development GO:0002076 9.61 BGLAP LRP5 RUNX2
21 positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus GO:1901522 9.59 BMP2 RUNX2
22 regulation of odontogenesis of dentin-containing tooth GO:0042487 9.58 BMP2 RUNX2
23 mammary gland alveolus development GO:0060749 9.58 ESR1 TNFRSF11A TNFSF11
24 bone mineralization involved in bone maturation GO:0035630 9.57 BMP2 IGF1
25 TNFSF11-mediated signaling pathway GO:0071847 9.55 TNFRSF11A TNFSF11
26 bone mineralization GO:0030282 9.54 BGLAP BMP2
27 mammary gland branching involved in pregnancy GO:0060745 9.52 ESR1 VDR
28 skeletal system development GO:0001501 9.5 BGLAP BMP2 IGF1 PTH RUNX2 TNFRSF11B
29 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.49 TNFRSF11A TNFSF11
30 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.48 TNFRSF11A TNFSF11
31 bone resorption GO:0045453 9.46 ACP5 CTSK PTH TNFSF11
32 ossification GO:0001503 9.17 ACP5 BGLAP BMP2 RUNX2 SOST TNFRSF11A

Molecular functions related to Bone Resorption Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 CALCA IGF1 PTH

Sources for Bone Resorption Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....